| Date | Title | | | 12/09/10 | Rigel and AstraZeneca Awarded 'Licensing Deal of the Year' by Scrip for Fostamatinib Collaboration| SOUTH SAN FRANCISCO, Calif., Dec. 9, 2010 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it received the Licensing Deal of the Year award from Scrip Intelligence at the Sixth Annual Scrip Awards last month. The Award, presented jointly to Rigel and AstraZeneca, recognizes the significance of the collaboration forged by the companies to develop fostamatinib (previously referred to as R788) as a novel oral treatment for rheumatoid arthritis (RA). This is... |
|  | | 11/23/10 | Rigel to Present at Piper Jaffray Health Care Conference| SOUTH SAN FRANCISCO, Calif., Nov. 23, 2010 /PRNewswire via COMTEX/ --
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 22nd Annual Piper Jaffray Health Care Conference in New York on Wednesday, December 1st at 3:00 p.m. EST.
To access the live audio webcast or the subsequent archived recording, log on to http://www.rigel.com/. Please connect to Rigel's website s... |
| | | 11/02/10 | Rigel Announces Third Quarter 2010 Financial Results| SOUTH SAN FRANCISCO, Calif., Nov. 2, 2010 /PRNewswire via COMTEX/ --
Rigel Pharmaceuticals,Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2010.
For the third quarter of 2010, Rigel reported net income of $50.4 million, or $0.97 and $0.96 per basic and diluted share, respectively, compared to a net loss of $26.7 million, or $0.70 per basic and diluted share, in the third quarter of 2009. Basic weighted average shares outstanding f... |
| | | 10/28/10 | Rigel Announces Presentations at Two Investor Conferences| SOUTH SAN FRANCISCO, Calif., Oct 28, 2010 /PRNewswire via COMTEX/ --
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez, president and chief operating officer of Rigel, will present at two separate investor conferences in November. Details of each conference are as follows:
Oppenheimer 21st Annual Healthcare Conference
New York, NY
November 3, 1:35 p.m. EDT
Speaker: Raul R... |
| | | 09/29/10 | Rigel Earns Milestone Payments From AstraZeneca| Fostamatinib (R788) enters Phase 3 Clinical Program
SOUTH SAN FRANCISCO, Calif., Sept 29, 2010 /PRNewswire via COMTEX/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patient... |
| | | 09/22/10 | Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients| - Phase II Study Published in the New England Journal of Medicine
LONDON and SAN FRANCISCO, September 22, 2010 /PRNewswire-FirstCall/ --
AstraZeneca's (LSE: AZN) new oral syk inhibitor, fostamatinib (R788), recently in-licensed from Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), significantly improved outcomes of patients with rheumatoid arthritis (RA) who responded inadequately to ongoing treatment with methotrexate (MTX), according to phase II study data published in The New England Journal of ... |
| | | 09/09/10 | Rigel to Present at Stifel Nicolaus Healthcare Conference| SOUTH SAN FRANCISCO, Calif., Sept 09, 2010 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Stifel Nicolaus Healthcare Conference in Boston, MA on Thursday, September 16th at 9:45a.m. EDT.
To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes p... |
| | | 08/03/10 | Rigel Announces Second Quarter 2010 Financial Results| SOUTH SAN FRANCISCO, Calif., Aug 03, 2010 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter and six months ended June 30, 2010.
For the second quarter of 2010, Rigel reported a net income of $27.0 million, or $0.52 and $0.51 per basic and diluted share, respectively, compared to a net loss of $29.9 million, or $0.81 per basic and diluted share, in the same period of 2009. Basic weighted average shares outstanding for... |
| | | 07/28/10 | Rigel to Present at BMO Capital Markets Healthcare Conference| SOUTH SAN FRANCISCO, Calif., July 28, 2010 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at BMO Capital Markets 10th Annual Focus on Healthcare Conference in New York City on Thursday, August 5th at 2:15 p.m. EDT.
To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's webs... |
| | | 06/03/10 | Rigel Announces Presentation at Three Investor Conferences| SOUTH SAN FRANCISCO, Calif., June 3, 2010 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial officer of Rigel, will present at three separate investor conferences in June. Details of each conference are as follows:
Jefferies Global Life Sciences Conference
New York City, NY
June 10, 8:00 a.m. EST
Speaker: James M.... |
| | | 06/01/10 | Rigel Pharmaceuticals Names Raul Rodriguez President| Ryan Maynard and Dolly Vance Promoted to Executive Vice Presidents
SOUTH SAN FRANCISCO, Calif., June 1, 2010 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the promotion of three members of senior management, effective immediately. Raul R. Rodriguez has been named president in addition to his position of chief operating officer; Dolly Vance assumes the title general counsel and executive vice president of Corporate Affairs; and Ryan Maynard is executive vi... |
| | | 05/04/10 | Rigel Announces First Quarter 2010 Financial Results| SOUTH SAN FRANCISCO, Calif., May 4, 2010 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2010.
For the first quarter of 2010, Rigel reported a net loss of $22.3 million, or $0.43 per share, compared to a net loss of $29.9 million, or $0.82 per share, in the first quarter of 2009. Weighted average shares outstanding for the first quarters of 2010 and 2009 were 52.0 million and 36.7 million, respectively... |
| | | 04/30/10 | Rigel Receives Innovators Award of Excellence in Life Sciences| SOUTH SAN FRANCISCO, Calif., April 30, 2010 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) has been named one of the recipients of the 2010 Innovators Award of Excellence by the San Mateo County Economic Development Association (SAMCEDA). The award will be presented at the association's Innovators luncheon today at the Oracle Conference Center in Redwood City. Donald G. Payan, Rigel's co-founder, executive vice president and president of Discovery and Research will accept t... |
| | | 03/29/10 | Rigel Announces Expiry of Waiting Period Under Hart-Scott-Rodino Act for Licensing Agreement With Astrazeneca| SOUTH SAN FRANCISCO, Calif., March 29, 2010 /PRNewswire via COMTEX/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 relating to the license agreement between Rigel and AstraZeneca, the effectiveness of which was contingent on the expiration of the waiting period.
The now-effective licensing agreement, which was announced on February 16, 2010, grants AstraZeneca an exclusive worldwid... |
| | | 03/18/10 | Rigel to Webcast Investor Day on March 25, 2010| SOUTH SAN FRANCISCO, Calif., March 18, 2010 /PRNewswire via COMTEX/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will provide a live webcast for its Investor Day on March 25, 2010 at 10:00am EDT. Members of Rigel's senior management team will provide an overview of the company's current product pipeline.
The event will be webcast live and can be accessed from Rigel's website at www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the l... |
| | | 03/17/10 | Rigel to Present at Barclays Capital Healthcare Conference| SOUTH SAN FRANCISCO, Calif., March 17, 2010 /PRNewswire via COMTEX/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Barclays Capital 2010 Global Healthcare Conference in Miami, Florida on Tuesday, March 23 at 10:45 a.m. EDT.
To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website severa... |
| | | 03/05/10 | Rigel to Present at Cowen and Company Health Care Conference| SOUTH SAN FRANCISCO, Calif., March 5, 2010 /PRNewswire via COMTEX/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Cowen and Company 30th Annual Health Care Conferencein Boston, Massachusetts on Tuesday, March 9th at 3:45 p.m. EST.
To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website... |
| | | 03/02/10 | Rigel Announces Fourth Quarter and Year End 2009 Financial Results| SOUTH SAN FRANCISCO, Calif., March 2, 2010 /PRNewswire via COMTEX/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and year ended December 31, 2009.
For the fourth quarter of 2009, Rigel reported a net loss of $25.1 million, or $0.48 per share, compared to a net loss of $33.4 million, or $0.91 per share, in the fourth quarter of 2008. Weighted average shares outstanding for the fourth quarters of 2009 and 2008 were 51.8 million and 36.6 mil... |
| | | 02/16/10 | Rigel to Host Conference Call Today to Discuss Its Partnership With AstraZeneca on Fostamatinib Disodium (R788)| SOUTH SAN FRANCISCO, Calif., Feb 16, 2010 /PRNewswire via COMTEX/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that its senior management team will host a conference call, and simultaneous audio webcast, today at 8:30 a.m. EST (5:30 a.m. PST) to discuss its partnership with AstraZeneca for Rigel's late-stage investigational product, fostamatinib disodium (R788), for the treatment of rheumatoid arthritis and additional indications.
Conference Call and Webcast Information
To access t... |
| | | 02/16/10 | AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- Fostamatinib Disodium (R788) -- for the Treatment of Rheumatoid Arthritis (RA)| SOUTH SAN FRANCISCO, Calif., Feb 16, 2010 /PRNewswire via COMTEX/ -- AstraZeneca and Rigel Pharmaceuticals (Nasdaq: RIGL) today announced an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and additional indications. Fostamatinib disodium, which has completed a comprehensive phase 2 program, is the furthest developed oral Spleen Tyrosine Kinase (Syk) i... |
| | | 02/05/10 | Rigel to Present at BIO CEO & Investor Conference| SOUTH SAN FRANCISCO, Calif., Feb 05, 2010 /PRNewswire via COMTEX/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 12th Annual BIO CEO & Investor Conference in New York City on Monday, February 8th at 10:00 a.m. EST.
To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several min... |
| |
|
rigel in the news
